Premature Labor (Tocolysis) (Women’s and Male Health) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor – Drugs In Development, 2021, provides an overview of the Premature Labor (Women's Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Labor – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Premature Labor (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Women's Health).

– The pipeline guide reviews pipeline therapeutics for Premature Labor (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Premature Labor (Women's Health) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Premature Labor (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Premature Labor (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Dare Bioscience Inc

Egret Therapeutics

GlaxoSmithKline Plc

ILIAS Biologics Inc

Lipocine Inc

ObsEva SA

Seed Health Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Premature Labor (Tocolysis) - Overview

Premature Labor (Tocolysis) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Premature Labor (Tocolysis) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development

Dare Bioscience Inc

Egret Therapeutics

GlaxoSmithKline Plc

ILIAS Biologics Inc

Lipocine Inc

ObsEva SA

Seed Health Inc

Premature Labor (Tocolysis) - Drug Profiles

ebopiprant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyprogesterone caproate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

progesterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein for Premature Labor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

retosiban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Acute Inflammation and Premature Labor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Premature Labor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMSC-0204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Labor (Tocolysis) - Dormant Projects

Premature Labor (Tocolysis) - Discontinued Products

Premature Labor (Tocolysis) - Product Development Milestones

Featured News & Press Releases

Jul 02, 2021: ObsEva to present Ebopiprant (OBE022) data at the Society for Reproductive Investigation 68th Annual Meeting

Jun 10, 2021: ObsEva presents prolong phase 2a proof-of-concept data on Ebopiprant (OBE022) for the treatment of spontaneous preterm labor at the RCOG Virtual World Congress 2021

Jun 02, 2021: ObsEva announces oral presentation at the RCOG Virtual World Congress 2021

Nov 16, 2020: ObsEva reports positive topline results of the prolong proof-of-concept trial of Ebopiprant (OBE022) for treatment of preterm labor

Aug 19, 2020: Daré Bioscience announces funding award notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to support DARE-FRT1 phase 1 human clinical study for the prevention of preterm birth

Jan 15, 2020: ObsEva to provide update on OBE022 at JP Morgan Healthcare Conference in San Francisco

Oct 10, 2019: Daré Bioscience announces a poster presentation on a pharmacokinetic study of DARE-FRT1, in development for sustained-release progesterone therapy for pregnancy maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

Jul 26, 2019: ObsEva reports positive feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

Mar 13, 2019: ObsEva to present OBE022 clinical data for treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

Jan 22, 2019: ObsEva SA reports initial good safety of OBE022 in pregnant women with preterm labour and announces start of part B of the PROLONG trial

Oct 30, 2018: Dare Bioscience to present preclinical data of DARE-FRT1 at AAPS 2018 meeting

Mar 01, 2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting

Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting

Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Premature Labor (Tocolysis), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Premature Labor (Tocolysis) – Pipeline by Dare Bioscience Inc, 2021

Premature Labor (Tocolysis) – Pipeline by Egret Therapeutics, 2021

Premature Labor (Tocolysis) – Pipeline by GlaxoSmithKline Plc, 2021

Premature Labor (Tocolysis) – Pipeline by ILIAS Biologics Inc, 2021

Premature Labor (Tocolysis) – Pipeline by Lipocine Inc, 2021

Premature Labor (Tocolysis) – Pipeline by ObsEva SA, 2021

Premature Labor (Tocolysis) – Pipeline by Seed Health Inc, 2021

Premature Labor (Tocolysis) – Dormant Projects, 2021

Premature Labor (Tocolysis) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Premature Labor (Tocolysis), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports